PORTO @ 
Archivio Istituzionale della Ricerca
IRIS è la soluzione IT che facilita la raccolta e la gestione dei dati relativi alle attività e ai prodotti della ricerca. Fornisce a ricercatori, amministratori e valutatori gli strumenti per monitorare i risultati della ricerca, aumentarne la visibilità e allocare in modo efficace le risorse disponibili.
EnglishWe discuss several innovative phase I and phase I--II designs for early phase cancer clinical trial with drug combinations focusing on continuous dose levels of both agents. For phase I trials with drug combinations, the main objective is to estimate the maximum tolerated dose (MTD) curve in the two-dimensional Cartesian plane. A parametric model is used to describe the relationship between the doses of the two agents and the probability of dose-limiting toxicity (DLT). Trial design proceeds using cohorts of two patients receiving doses according to univariate escalation with overdose control (EWOC) or continual reassessment method (CRM). At the end of the trial, the MTD is estimated as a function of Bayes estimates of the model parameters. Furthermore, we present the model where a fraction of DLTs can be attributed to one or both agents, and show how the parametric designs can be adapted to account for an unknown fraction of attributable DLTs. We also consider the inclusion of a binary baseline covariate to describe sub-groups with different frailty levels. In phase I--II trials, it may not be possible to evaluate efficacy in a short window of time. In this case, two-stage designs are frequently employed. First, a set of maximum tolerated dose combinations is selected. Next, the selected set is then tested for efficacy, sometimes in a different patient population than that used in the first stage. We discuss binary and time-to-event endpoints to identify dose combinations along the MTD curve with maximum probability of efficacy in the second stage.
Designs of Early Phase Cancer Trials with Drug Combinations / Jimenez Moro, Jose Luis; Marcio Augusto Diniz, ; Andre, Rogatko; Mourad, Tighiouart. - (2021), pp. 131-160. [10.1007/978-3-030-72437-5_7]
| Titolo: | Designs of Early Phase Cancer Trials with Drug Combinations | |
| Autori: | ||
| Data di pubblicazione: | 2021 | |
| Titolo del libro: | Modern Statistical Methods for Health Research | |
| Abstract: | We discuss several innovative phase I and phase I--II designs for early phase cancer clinical tri...al with drug combinations focusing on continuous dose levels of both agents. For phase I trials with drug combinations, the main objective is to estimate the maximum tolerated dose (MTD) curve in the two-dimensional Cartesian plane. A parametric model is used to describe the relationship between the doses of the two agents and the probability of dose-limiting toxicity (DLT). Trial design proceeds using cohorts of two patients receiving doses according to univariate escalation with overdose control (EWOC) or continual reassessment method (CRM). At the end of the trial, the MTD is estimated as a function of Bayes estimates of the model parameters. Furthermore, we present the model where a fraction of DLTs can be attributed to one or both agents, and show how the parametric designs can be adapted to account for an unknown fraction of attributable DLTs. We also consider the inclusion of a binary baseline covariate to describe sub-groups with different frailty levels. In phase I--II trials, it may not be possible to evaluate efficacy in a short window of time. In this case, two-stage designs are frequently employed. First, a set of maximum tolerated dose combinations is selected. Next, the selected set is then tested for efficacy, sometimes in a different patient population than that used in the first stage. We discuss binary and time-to-event endpoints to identify dose combinations along the MTD curve with maximum probability of efficacy in the second stage. | |
| ISBN: | 978-3-030-72437-5 | |
| Appare nelle tipologie: | 2.1 Contributo in volume (Capitolo o Saggio) |
File in questo prodotto:
| File | Descrizione | Tipologia | Licenza | |
|---|---|---|---|---|
| 2021_Book_ModernStatisticalMethodsForHea.pdf | 2a Post-print versione editoriale / Version of Record | Non Pubblico - Accesso privato/ristretto | Administrator Richiedi una copia | |
| 10.1007_978-3-030-72437-5_7.pdf | 2a Post-print versione editoriale / Version of Record | PUBBLICO - Tutti i diritti riservati | Visibile a tuttiVisualizza/Apri |
http://hdl.handle.net/11583/2938556
Copyright © 2022